SPARCL1 and metabolic dysfunction-associated steatotic liver disease: We concluded that HSPD1/MMP14/ITGB1/miR-6881-5P/Lnc-SPARCL1-1:2 panel expression has a potential in the diagnosis of NASH, and also in differentiation between NAFLD without steatosis, NAFLD with simple steatosis and NASH.